ATE413868T1 - Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin - Google Patents

Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Info

Publication number
ATE413868T1
ATE413868T1 AT04798662T AT04798662T ATE413868T1 AT E413868 T1 ATE413868 T1 AT E413868T1 AT 04798662 T AT04798662 T AT 04798662T AT 04798662 T AT04798662 T AT 04798662T AT E413868 T1 ATE413868 T1 AT E413868T1
Authority
AT
Austria
Prior art keywords
hydrofluoralkan
formulation containing
spray formulation
pharmaceutical spray
acylated cyclodextrin
Prior art date
Application number
AT04798662T
Other languages
German (de)
English (en)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE413868T1 publication Critical patent/ATE413868T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT04798662T 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin ATE413868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Publications (1)

Publication Number Publication Date
ATE413868T1 true ATE413868T1 (de) 2008-11-15

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798662T ATE413868T1 (de) 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Country Status (23)

Country Link
US (1) US20070104652A1 (OSRAM)
EP (1) EP1708679B1 (OSRAM)
JP (1) JP4950666B2 (OSRAM)
KR (1) KR20060118509A (OSRAM)
CN (1) CN100592908C (OSRAM)
AT (1) ATE413868T1 (OSRAM)
AU (1) AU2004294775B2 (OSRAM)
BR (1) BRPI0416992A (OSRAM)
CA (1) CA2546441C (OSRAM)
CY (1) CY1108753T1 (OSRAM)
DE (1) DE602004017783D1 (OSRAM)
DK (1) DK1708679T3 (OSRAM)
ES (1) ES2314469T3 (OSRAM)
IL (1) IL175659A (OSRAM)
MX (1) MXPA06005643A (OSRAM)
NO (1) NO20062969L (OSRAM)
NZ (1) NZ547355A (OSRAM)
PL (1) PL1708679T3 (OSRAM)
PT (1) PT1708679E (OSRAM)
SE (1) SE0303179D0 (OSRAM)
SI (1) SI1708679T1 (OSRAM)
WO (1) WO2005053637A2 (OSRAM)
ZA (1) ZA200604330B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
WO2023127219A1 (ja) * 2021-12-28 2023-07-06 リンテック株式会社 シリコーン系粘着剤、粘着シートおよび両面粘着シート

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW224942B (OSRAM) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
US20070104652A1 (en) 2007-05-10
SI1708679T1 (sl) 2009-04-30
CN101087600A (zh) 2007-12-12
WO2005053637A2 (en) 2005-06-16
HK1108390A1 (zh) 2008-05-09
PT1708679E (pt) 2008-12-29
NZ547355A (en) 2009-05-31
PL1708679T3 (pl) 2009-04-30
AU2004294775A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
IL175659A (en) 2010-02-17
DE602004017783D1 (de) 2008-12-24
CA2546441A1 (en) 2005-06-16
IL175659A0 (en) 2006-09-05
AU2004294775B2 (en) 2007-12-20
DK1708679T3 (da) 2009-02-16
CY1108753T1 (el) 2014-04-09
CA2546441C (en) 2011-11-22
CN100592908C (zh) 2010-03-03
ES2314469T3 (es) 2009-03-16
MXPA06005643A (es) 2006-08-17
WO2005053637A3 (en) 2007-06-28
NO20062969L (no) 2006-08-25
EP1708679B1 (en) 2008-11-12
JP2007515401A (ja) 2007-06-14
BRPI0416992A (pt) 2007-02-06
EP1708679A2 (en) 2006-10-11
ZA200604330B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
DE60335797D1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
IL169469A (en) Folic acid derivatives containing disulfide bonds, their pharmaceutical compositions and their use
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
CY2016024I2 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
NZ534040A (en) Metered dose inhaler
TWI315203B (en) Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments
TW200605870A (en) Topical methadone compositions and methods for using the same
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
NO20090554L (no) Farmasoytiske preparater av memantin
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
WO2001066601A8 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
CY1110664T1 (el) Ενδορινικες συνθεσετς
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
WO2006089993A3 (es) Procedimiento de obtención de hidrogeles de ciclodextrinas con glicidiléteres, las composiciones obtenidas y sus aplicaciones
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
NO20076120L (no) Stabile nanopartikkelformuleringer
DE602004017783D1 (de) Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1708679

Country of ref document: EP